CareDx Inc (CDNA)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $4.09B
Last updated: Nov 17, 2026 at 4:43 PM ET
CareDx Inc (CDNA) Stock Chart
CareDx (CDNA) has a latest price of $74.56 on Nov 17, 2026, 17.9% below its 52-week high of $90.87. Its price rose 367.9% over the past 12 months. The month-end price rose 2,294.8% over the 10 years through Oct 2026, a compound annual rate of 37.4%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $91.52 in Jun 2021 and its lowest $0.87 in Apr 2017, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart CDNA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for CDNA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 60.3%, and over 6 months it rose 263.2%. The month-end price rose 1,515.7% over the 3 years through Oct 2026, a compound annual rate of 152.8%.
| Period | Change |
|---|---|
| 1 month | +11.2% |
| 3 months | +60.3% |
| 6 months | +263.2% |
| 12 months | +367.9% |
| 12 months, with dividends | +367.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +1,515.7% | +152.8% |
| 5 years | +71.4% | +11.4% |
| 10 years | +2,294.8% | +37.4% |
Price by Year
Its best calendar year was 2018, when the price rose 242.5%, and its weakest was 2022, when it fell 74.9%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $87.41 | +364.0% |
| 2025 | $18.84 | -12.0% |
| 2024 | $21.41 | +78.4% |
| 2023 | $12.00 | +5.2% |
| 2022 | $11.41 | -74.9% |
| 2021 | $45.48 | -37.2% |
| 2020 | $72.45 | +235.9% |
| 2019 | $21.57 | -14.2% |
| 2018 | $25.14 | +242.5% |
| 2017 | $7.34 | +171.9% |
Trading Range
The price is 10.8% above its 50-day average of $67.28 and 100.2% above its 200-day average of $37.24.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $74.56 | |
| 52-week high | $90.87 | -17.9% |
| 52-week low | $15.56 | +379.2% |
| 50-day average | $67.28 | +10.8% |
| 200-day average | $37.24 | +100.2% |
Price Risk
Over 3 years, its largest fall from a peak was 66.0%.
| Measure | Value |
|---|---|
| 1-year beta | 1.29 |
| Largest fall, 1 year | -23.6% |
| Largest fall, 3 years | -66.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About CDNA
What is CDNA's 1-year price change?
CareDx's price rose 367.9% over the past 12 months. With dividends included, the 12-month total return was 367.9%.
What is CDNA's 5-year price change?
CareDx's month-end price rose 71.4% over the 5 years through Oct 2026, a compound annual rate of 11.4%. These figures leave out dividends.
What is CDNA's 52-week high and low?
CareDx's 52-week high is $90.87 and its 52-week low is $15.56. Its latest price of $74.56 on Nov 17, 2026 is 17.9% below the high.
What is CDNA's beta?
CareDx's 1-year beta against the S&P 500 is 1.29, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 23.6%.
Is the CDNA chart free?
Yes. Advanced Charting for CDNA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
CDNA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts